Related Experiment Video
Updated: Jan 16, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Proton Therapy May Reduce the Risk of Cancer Progression During Immune Checkpoint Inhibitor Therapy: A Propensity
Cong Bo1, Zhenhuan Lv2, Hong Zhang3
1Departments of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Purpose:
Intensity modulated proton therapy (IMPT) may preserve the immune response more effectively than intensity modulated photon radiation therapy (IMRT) owing to its dosimetric advantages, making it a potentially superior modality in immunotherapy. This study aimed to evaluate the clinical benefits of IMPT versus IMRT during immune checkpoint inhibitors (ICIs) treatment.
Methods And Materials:
We retrospectively analyzed the data of 466 patients (IMPT group, n = 109; IMRT group, n = 357) who received radiation therapy (RT) during ICI therapy between July 2022 and September 2024. Propensity score matching was applied to balance clinical characteristics. The primary endpoint was the duration of response (DoR). Secondary endpoints included progression-free survival (PFS) and post-RT adverse events. Kaplan-Meier and Cox proportional hazards regression were used to calculate survival curves and identify independent prognostic factors. The threshold used to dichotomize post-RT lymphocyte count was 0.5 × 109/L.
Results:
Baseline clinical characteristics were balanced after propensity score matching. The IMPT group showed significantly longer median DoR (17.7 vs 5.7 months; P = .0001) and PFS (18.8 vs 6.8 months; P < .0001) than the IMRT group. Multivariable regression revealed IMPT to be an independent predictor of improved DoR (hazard ratio, 0.34; 95% CI, 0.21-0.55; P < .0001) and PFS (hazard ratio, 0.36; 95% CI, 0.25-0.52; P < .0001). Subgroup analyses suggested greater benefit of IMPT over IMRT in patients with a Charlson Comorbidity Index ≥4, lung cancer, advanced-stage disease, or those receiving palliative, thoracic, or abdominal/pelvic RT. Higher post-RT lymphocyte counts in the IMPT group showed potential correlation with improved DoR and PFS. Additionally, the IMPT group had fewer grade ≥2 post-RT adverse events (P = .012).
Conclusions:
IMPT is linked to enhanced efficacy of ICIs, compared with IMRT, by improving DoR and PFS with tolerable adverse effects. Higher post-RT lymphocyte counts may be associated with improved survival in patients receiving IMPT during ICI therapy. These findings suggest that IMPT may be a preferable option for preserving immune function, thereby optimizing outcomes during immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...